Recent news regarding opioid medication dependence among the American population has led many to question the longevity of such treatments and pose the question; what alternatives can be used?
Opioid abuse is a global epidemic, with between 26.4 million to 36 million people worldwide affected. In the U.S., it is estimated that 2.1 million people are suffering the effects of opioid addiction in a country where painkiller prescriptions have increased by 104 percent between 2000 and 2010. While the increase in prescriptions has not results in improvements in pain or disability, prescription opioid abuse claimed the lives of 20,000 Americans in 2014 alone. While alternatives to opioids can include corticosteroids, neurostimulators and injections, a new approach could lie in Physical Therapy1.
In the Physical Therapy industry, the rise of smart technology is changing the way clinicians assess and prescribe treatments for patients experiencing chronic pain. One such solution from biotech company dorsaVi is providing just that – a new technology that allows clinicians across the globe to enhance their patient’s quality of life by developing tailored treatment programs which aim to reduce the incidence and prevalence of chronic pain.
In the clinical space, dorsaVi’s FDA cleared ViMove and ViMove2 wearable sensor technology is taking patient care to new heights and could assist in reducing prescription medication dependence from drugs such as opioids by providing a non-invasive, medication-free alternative to addressing chronic pain.
By blending sophisticated software algorithms with mini sensor technology and easy-to-use software, ViMove2 is set to revolutionize the Physical Therapy industry, providing clinicians with new, never-before seen insights into how their patient’s movements could be contributing to their pain and discomfort.
Says Andrew Ronchi, dorsaVi CEO “The industry is screaming for a shake up, with medication abuse from drugs such as opioids leading to tens of thousands of deaths in America alone. While there are many alternatives to managing pain, a non-invasive, medication-free approach such as ViMove2 could be the catalyst for change in the industry”.
In conjunction with ViMove2, dorsaVi’s research arm has launched a US-based low back pain and movement registry to understand how movement is altered in people with low back pain and how treatments can change these movement patterns.
A landmark Randomized Controlled Trial, published in medical journal BMC Musculoskeletal, showed that patients who used dorsaVi ViMove technology achieved the following:
- At 10 weeks, there were significant improvement in all key measures. Improvements were sustained or improved at 12 months.
- ViMove patients were three times more likely to have clinically important improvements (>30% over baseline) in activity limitations vs standard care at 12 months.
- 2.5 times more likely to have clinically important improvements (>30% over baseline) in activity limitation vs standard care at 12 months.
To learn more about the Randomized Controlled Trial, please click here.